Cargando…
Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384
Multidrug resistance (MDR) remains a critical bottleneck in successful treatment of osteosarcoma (OS). Luteolin is a flavonoid compound that has been verified to increase the sensitivity to antineoplastic drugs in many tumors. However, its roles in reversing MDR of OS and the potential underlying me...
Autores principales: | Qin, Tao, Zhu, Wenjing, Kan, Xiaoli, Li, Ling, Wu, Dapeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048097/ https://www.ncbi.nlm.nih.gov/pubmed/35493691 http://dx.doi.org/10.1016/j.jbo.2022.100429 |
Ejemplares similares
-
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells
por: Lee, Yu-Hsien, et al.
Publicado: (2017) -
Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/pleiotrophin axis
por: Yao, Yuanyuan, et al.
Publicado: (2019) -
miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN
por: He, Ming, et al.
Publicado: (2019) -
Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
por: Wu, Dapeng, et al.
Publicado: (2017) -
CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma
por: Gerardo-Ramírez, Monserrat, et al.
Publicado: (2022)